Phathom Pharmaceuticals, Inc. (PHAT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Phathom Pharmaceuticals, Inc. (PHAT) Healthcare & Pipeline Overview

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in gastrointestinal disease treatments, primarily focusing on vonoprazan, a potassium-competitive acid blocker (P-CAB). With rights in the US, Europe, and Canada, Phathom is positioned to address significant unmet needs in acid-related disorders, including erosive GERD and H. pylori infection.

What Is the Investment Thesis for PHAT?

Phathom Pharmaceuticals, Inc. presents a notable research candidate due to its focus on vonoprazan, a novel P-CAB with the potential to disrupt the gastrointestinal therapeutics market. The company's lead product candidate is undergoing Phase III clinical trials for erosive GERD and H. pylori infection, both large and underserved markets. Positive clinical trial results and subsequent regulatory approvals could drive significant revenue growth. Phathom's market capitalization of $677M reflects investor confidence in its pipeline and management team. Key value drivers include successful commercialization of vonoprazan, expansion into new indications, and potential partnerships or acquisitions. However, potential risks include clinical trial failures, regulatory setbacks, and competition from established pharmaceutical companies.

Based on FMP financials and quantitative analysis

PHAT Key Highlights

Market capitalization of $677M, reflecting investor valuation of Phathom's pipeline and potential.

• Gross margin of 84.9%, indicating strong pricing power and efficient cost management in future commercialization.
• Beta of 0.61, suggesting lower volatility compared to the overall market.
• Focus on vonoprazan, a novel P-CAB with potential advantages over existing PPI therapies.
• Ongoing Phase III clinical trials for erosive GERD and H. pylori infection, representing significant market opportunities.

Who Are PHAT's Competitors?

PHAT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PHAT's Key Strengths?

Novel P-CAB mechanism of action with potential advantages over PPIs.

• Rights to vonoprazan in key markets (US, Europe, Canada).
• Focus on large and underserved markets (erosive GERD, H. pylori infection).
• Experienced management team with a track record in pharmaceutical development and commercialization.

What Are PHAT's Weaknesses?

Clinical-stage company with no currently marketed products.

• Reliance on the success of vonoprazan.
• High operating expenses associated with clinical trials and regulatory submissions.
• Negative profit margin.

What Could Drive PHAT Stock Higher?

Data readouts from Phase III clinical trials for erosive GERD.

• Data readouts from Phase III clinical trials for H. pylori infection.
• Regulatory submissions for vonoprazan in the United States, Europe, and Canada.
• Progress in expanding the clinical development program for vonoprazan into new indications.
• Potential strategic partnerships and acquisitions.

What Are the Key Risks for PHAT?

Financial-distress signal — its Altman Z-Score of -5.04 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures could delay or prevent regulatory approvals.
• Regulatory setbacks could increase development costs and timelines.
• Competition from established pharmaceutical companies could limit market share.
• Patent challenges could erode exclusivity.
• Dependence on vonoprazan.

What Are the Growth Opportunities for PHAT?

• Expansion into New Indications: Phathom has the opportunity to expand the use of vonoprazan into additional gastrointestinal indications beyond erosive GERD and H. pylori infection. This could include conditions such as non-erosive reflux disease (NERD) and other acid-related disorders. The market for these indications is substantial, potentially adding hundreds of millions of dollars in revenue. Timeline: Ongoing research and development efforts, with potential clinical trials and regulatory submissions in the next 3-5 years.
• Geographic Expansion: Phathom currently holds the rights to vonoprazan in the United States, Europe, and Canada. Expanding into other geographic markets, such as Asia and Latin America, could significantly increase the company's revenue potential. These regions have large populations and growing healthcare spending. Timeline: Strategic partnerships and regulatory submissions in the next 2-4 years.
• Strategic Partnerships and Acquisitions: Phathom could pursue strategic partnerships or acquisitions to expand its product pipeline and market reach. This could involve licensing or acquiring other GI therapeutics or technologies. Such deals could provide access to new markets and accelerate growth. Timeline: Ongoing business development efforts, with potential deals in the next 1-3 years.
• Lifecycle Management: Phathom can extend the lifecycle of vonoprazan through various strategies, such as developing new formulations, dosages, or delivery methods. This could help to maintain market share and revenue growth over the long term. Timeline: Continuous product development and innovation.
• Direct-to-Consumer Marketing: Upon regulatory approval and commercialization, Phathom can leverage direct-to-consumer (DTC) marketing to drive awareness and adoption of vonoprazan. This could involve advertising campaigns, online marketing, and patient education initiatives. Effective DTC marketing can help to increase market share and revenue. Timeline: Post-commercialization, ongoing marketing efforts.

What Are PHAT's Competitive Advantages?

• Patent protection for vonoprazan, providing exclusivity in key markets.
• Clinical data demonstrating superior efficacy and safety compared to existing therapies.
• Established relationships with key opinion leaders and healthcare providers.
• Regulatory expertise and track record in securing approvals for pharmaceutical products.

What Does PHAT Do?

Phathom Pharmaceuticals, Inc. was founded in 2018 and is headquartered in Florham Park, New Jersey. The company is dedicated to developing and commercializing innovative treatments for gastrointestinal (GI) diseases and disorders. Phathom's primary focus is on vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan is designed to block acid secretion in the stomach more effectively than traditional proton pump inhibitors (PPIs). Phathom holds the rights to vonoprazan in the United States, Europe, and Canada. The company is currently pursuing regulatory approvals for vonoprazan in various indications, including the treatment of erosive gastroesophageal reflux disease (erosive GERD) and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. These conditions represent significant unmet medical needs, affecting millions of people worldwide. Phathom's clinical development programs are designed to demonstrate the superior efficacy and safety of vonoprazan compared to existing therapies. The company's strategic vision is to become a leading player in the GI therapeutics market by providing innovative solutions that improve patient outcomes and quality of life.

What Products and Services Does PHAT Offer?

• Develops and commercializes treatments for gastrointestinal diseases.
• Focuses on vonoprazan, a potassium-competitive acid blocker (P-CAB).
• Conducts Phase III clinical trials for erosive gastroesophageal reflux disease (erosive GERD).
• Conducts Phase III clinical trials in combination with antibiotics for Helicobacter pylori (H. pylori) infection.
• Holds rights to vonoprazan in the United States, Europe, and Canada.
• Seeks regulatory approvals for vonoprazan in various indications.

How Does PHAT Make Money?

• Develops and patents novel pharmaceutical products.
• Conducts clinical trials to demonstrate efficacy and safety.
• Seeks regulatory approval from agencies like the FDA and EMA.
• Commercializes approved products through sales and marketing efforts.

What Industry Does PHAT Operate In?

Phathom Pharmaceuticals, Inc. operates in the biotechnology industry, which is characterized by high growth potential and significant investment in research and development. The gastrointestinal therapeutics market is a large and growing segment, driven by the increasing prevalence of conditions such as GERD and H. pylori infection. Phathom's focus on vonoprazan positions it to compete with established pharmaceutical companies that market PPIs and other GI drugs. The company's success will depend on its ability to demonstrate the superior efficacy and safety of vonoprazan in clinical trials and to secure regulatory approvals in key markets.

Who Are PHAT's Key Customers?

• Patients suffering from gastrointestinal diseases, particularly erosive GERD and H. pylori infection.
• Healthcare providers who prescribe treatments for these conditions.
• Hospitals and clinics that administer these treatments.
• Pharmacies that dispense these medications.

Phathom Pharmaceuticals, Inc. (PHAT) Valuation Context

Valued at $677M, PHAT is classified as a small-cap stock. Analyst price targets span from $10.00 to $22.00, with a consensus of $17.60. At the current price of $8.37, that implies approximately 110% upside potential. Relative to its peer group, PHAT's quantitative score of 17/100 is below the peer average of 85/100.

PHAT Revenue & Earnings Trend

In Q2 FY2026, PHAT generated $74.3M in top-line revenue, marking a sequential increase of 27.4%. The company recorded a net loss of $17.6M, with diluted EPS of $-0.21. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this small-cap Healthcare company. Across the four most recent quarters, PHAT averaged $-0.32 in diluted EPS.

Company Profile

Phathom Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Florham Park, US. The company is led by CEO Steven L. Basta. PHAT has traded publicly since 2019.

Return on equity for Phathom Pharmaceuticals, Inc. stands at 25.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -30.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.92 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -12.4%, the inverse of the P/E and a quick read on earnings relative to price.

Phathom Pharmaceuticals, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.04 places it in the distress zone, a signal of elevated financial risk.

Phathom Pharmaceuticals, Inc. has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a mixed record worth weighing.

Over the past six months, Phathom Pharmaceuticals, Inc. insiders filed 13 SEC Form 4 transactions — 4 sales and 9 purchases. On net that is roughly 167K shares acquired (about $21K) — insiders putting money in tends to read as conviction.

PHAT Financials

PHAT Latest News

PHAT Analyst Consensus

PHAT MoonshotScore

Phathom Pharmaceuticals, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources